FY2026 · ended Dec 31, 2025 · Revenue $234.60M, +157.0% YoY · Filed Sep 21, 2026
Anaptysbio, Inc. (ANAB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Dec 31, 2025, it reported revenue of $234.6 million and a net loss of $13.2 million. Free cash flow was $19.6 million. As of Jun 30, 2026 it held $164.1 million in cash and investments and $13.1 million in total debt.
Revenue (TTM)
$232.39M
+107.7% vs year-ago TTM
Net income (TTM)
$-26.79M
+81.0% vs year-ago TTM
Operating cash flow (TTM)
$4.48M
+104.1% vs year-ago TTM
Free cash flow (TTM)
$4.41M
+104.0% vs year-ago TTM
EPS (TTM)
$-0.90
+80.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
29.90M
+2.7% vs prior year
Net cash
$151.05M
FY 2026
Operating margin
94.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANAB (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1370053
- Former names
- ANAPTYSBIO INC (until Jun 12, 2019); ANAPTYS BIOSCIENCES INC (until Nov 20, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M |
| Operating income | $226.9M | $66.2M | -$164.4M | -$115.2M | -$56.8M |
| Net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M | -$57.8M |
| Diluted EPS | -$0.44 | -$4.92 | -$6.08 | -$4.57 | -$2.11 |
| Operating cash flow | $19.7M | -$135.3M | -$120.8M | -$73.6M | -$45.9M |
| Free cash flow | $19.6M | -$135.7M | -$121.6M | -$74.0M | -$47.3M |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M |
| Stockholders' equity | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M |
| Cash and investments | $211.6M | $320.8M | $417.9M | $584.2M | $615.2M |
| Total debt | $14,112 | $16.0M | $17.8M | $19.4M | $21.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-KT | Transition report | Sep 21, 2026 | Jun 30, 2026 |
| 8-K | Current report | Sep 21, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 30, 2026 | Jul 28, 2026 |
| ARS | Annual report to shareholders | Jun 29, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement
|
Jun 22, 2026 | Jun 15, 2026 |
All 725 Anaptysbio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.